NCT05313620View on ClinicalTrials.gov

Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events

PHASE4RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Ulcerative ColitisThromboembolism
Interventions
DRUG

Tofacitinib

Tofacitinib 5 MG/day per clinical practice

DRUG

Infliximab Adalimumab y Golimumab

Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice or adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus) per clinical practice or or golimumab (subcutaneus 50 mg milligram(s)-subcutaneus) per clinical practice.

Trial Locations (1)

28006

RECRUITING

Hospital Universitario de La Princesa, Madrid

All Listed Sponsors
lead

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

OTHER